Yunyu Mao

Current status and future development of anti-HIV chimeric antigen receptor T-cell therapy.

Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing.

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo.

Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study.